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Autoimmune connective tissue diseases are a heterogeneous group of pathologies that aﬀect about 10% of world population with
chronic evolution in 20%–80%. Inﬂammation in autoimmune diseases may lead to serious damage to other organs including the
gastrointestinal tract. Gastrointestinal tract involvement in these patients may also due to both a direct action of antibodies
against organs and pharmacological therapies. Dysphagia is one of the most important symptom, and it is caused by failure of
the swallowing function and may lead to aspiration pneumonia, malnutrition, dehydration, weight loss, and airway obstruction.
The videoﬂuorographic swallowing study is a key diagnostic tool in the detection of swallowing disorders, allowing to make an
early diagnosis and to reduce the risk of gastrointestinal and pulmonary complications. This technique helps to identify both
functional and structural anomalies of the anatomic chain involved in swallowing function. The aim of this review is to
systematically analyze the basis of the pathological involvement of the swallowing function for each rheumatological disease and
to show the main features of the videoﬂuorographic study that may be encountered in these patients.
1. Introduction
Autoimmune connective tissue diseases are a heterogeneous
group of pathologies that aﬀect about 10% of world popula-
tion with chronic evolution in 20% up to 80% [1, 2]. Rheu-
matic diseases, arthritis and other diseases of muscles,
joints, and bones, are common and have an important
impact on the health and well-being of nearly 50 million
Americans [1, 2]. Children maybe also be aﬀected: it has been
reported that nearly 300,000 American children suﬀer from
rheumatic diseases and the most common is juvenile idio-
pathic arthritis [2].
Inﬂammation and damage to joints may also lead to seri-
ous damage to other organs, being responsible of coexisting
disease and disability. For this reason, rheumatic diseases
are a more frequent cause of activity limitation than heart
disease, cancer, or diabetes [3].
The latest ﬁgures regarding rheumatic diseases show that
they led to $127.8 billion in medical costs in the U.S [2], more
than the $124.6 billion in costs for cancer care [4]. During the
early stages of rheumatic disease, most of the costs are related
to direct medical expenses for aggressive treatment regimens.
Thereafter, the cost proﬁle shifts with the incorporation of
indirect costs related to work limitations. Reducing indirect
costs, such as work limitations or even loss of work, can save
the U.S. more than $47 billion per year [5].
As described before, rheumatic diseases can cause dam-
age to vital organs, including the lungs, heart, nervous sys-
tem, kidneys, skin, and eyes [6], and the majority of
patients aﬀected develops gastrointestinal tract involvement
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that may be caused by a direct action of antibodies against
organs but also depends on pharmacological therapies [7].
In order to prevent life-threatening complications, early
diagnosis and treatment of dysphagia is very important, con-
sidering also that it can lead to pneumonia, malnutrition,
dehydration, and increased mortality [8].
There are over 30 autoimmune rheumatic diseases. Some
of the most common are rheumatoid arthritis (RA), systemic
lupus erythematosus (SLE), gout, systemic scleroderma
(SSc), inﬂammatory myopathies (IM), juvenile idiopathic
arthritis (JDM), Sjogren’s syndrome (SS), sarcoidosis, spon-
dylarthritides, and polymyalgia rheumatic and systemic
vasculitis. Among them, esophageal function is more often
impaired in SSc, IM, sarcoidosis, and SS [9, 10].
Moreover, orofacial manifestations occur frequently in
rheumatic diseases and usually represent the early signs of dis-
ease or of its activity that are still neglected in clinical practice.
2. Anatomy and Physiology of Swallowing
Swallowing is a complex function enabling forwarding of
food and saliva from the mouth into the stomach. Eating
and swallowing in particular are complex behaviors that
involve both volitional and reﬂexive mechanism of diﬀerent
nerves and muscles. During deglutition, it is important not
just a correct bolus transit from oral cavity to the esophagus
but also to manage airway protection. We may recognize
three diﬀerent phases of swallowing process: the oral, pha-
ryngeal, and esophageal ones. Oral phase is also divided into
preparatory and propulsive stages.
After liquid assumption into the mouth, the bolus is
ﬁrstly held on the tongue surface against the hard palate with
the upper dental arch or in the anterior part of the mouth
ﬂoor. In order to prevent the liquid bolus leaking into the
oropharynx before the swallow, the oral cavity is excluded
posteriorly by the soft palate and the tongue contact.
Propulsive stage is dominated by tongue movements that
permit a reduction in size and to soften food through masti-
cation and salivation and allow the transit of the bolus into
the pharynx.
Pharyngeal phase is characterized by two crucial biologi-
cal features: food passage through the pharynx and the upper
esophageal sphincter (UES) to the esophagus and airway pro-
tection, excluding larynx and trachea from the pharynx.
After that, the bolus transits to the esophagus, a tubular
structure, that begins with the lower part of the UES and ends
with lower esophageal sphincter (LES), which is also ten-
sioned to prevent regurgitation from the stomach. The ﬁrst
part of the organ (cervical esophagus) is mainly composed
by striated muscle, while the thoracic esophagus (second
and third part) is composed by smooth muscle. Thus, bolus
transit starts with voluntary movements that allow the
passage through UES; on the other hand, the transit in
the thoracic esophagus is regulated by autonomic nervous
system. The peristalsis wave involved in the last two-third
of the esophagus is composed by two main parts: the ﬁrst
is characterized by relaxation and the second by contrac-
tion to propel the bolus. Also, gravity has a role in the
propulsion phase [11].
3. VFSS
The videoﬂuorographic swallowing study (VFSS) or modi-
ﬁed barium swallowing study [12] is a useful radiologic pro-
cedure to detect swallowing disorders, allowing to make an
early diagnosis and to reduce the risk of gastrointestinal
and pulmonary complications [13, 14].
VFSS helps to identify not only functional but also struc-
tural anomalies of anatomic regions studied during the pro-
cedure [15].
Sequential videoradiographic images are captured during
all the phases of swallowing [12].
Awareness and cooperation by the patient are essential in
order to perform a diagnostic procedure and having some-
thing bymouth, and smoking or chewing should be forbidden
for many hours prior to the VFSS [15]. After positioning
the patient in the lateral view, the VFFS starts and evaluates
pharyngoesophageal segment, lips, tongue, nasal cavity, and
cervical rachis [16].
Lateral view is essential to study critical valves opening
and closure and pressure modiﬁcations which oropharyngeal
and cervical esophagus are subjected to during swallowing.
The anterior-posterior view is fundamental to assess struc-
tural and functional asymmetry [12].
Swallowing abnormalities do not always occur during the
ﬁrst swallows, so it is generally necessary to repeat several
swallowing in order to make anomalies manifest.
The radiologist has to focus on bolus’ timing, ﬂowing and
clearance, and the airway invasion, detecting when aspiration
and/or penetration occurs [17].
During aspiration, ingested material goes into the trachea
below the level of the true vocal folds, while during pene-
tration, bolus material moves into the laryngeal vestibule,
down to the level of the vocal folds, without crossing the
vocal folds [18].
The medical report of VFSS (Table 1) should contain
information related to the patient anamnesis and disease
and those desumed during the procedure [17].
4. Swallowing Disorders
Dysphagia could be deﬁned as the diﬃculty or failure of this
mechanism and is often associated with impaired swallowing
function. It is a condition in which disruption of the swallow-
ing process interferes with a patient’s ability to eat but also
can result in aspiration pneumonia, malnutrition, dehydra-
tion, weight loss, and airway obstruction. For this reason,
compromised swallowing may inﬂuence also safety, eﬃ-
ciency, or adequacy of nutritional intake.
Swallowing disorders can occur at any stage in the swal-
lowing process, which are, as described before: oral phase,
pharyngeal phase, and esophageal phase. The ﬁrst is charac-
terized by chewing and moving food or liquid into the throat,
the second consists in starting the swallowing reﬂex, squeez-
ing food down the throat, and closing oﬀ the airway to pre-
vent food or liquid from entering the airway (aspiration) or
to prevent choking, and the third results in relaxing and
tightening the openings at the top and bottom of the feeding
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tube in the throat (esophagus) and squeezing food through
the esophagus into the stomach.
Signs and symptoms of oral or pharyngeal dysphagia
include coughing or choking with swallowing, diﬃculty initi-
ating swallowing, food sticking in the throat, bringing food
back up, sometimes through the nose, sialorrhea, unex-
plained weight loss, change in dietary habits, nasal regurgita-
tion, change in voice or speech (wet voice) [19, 20], and
recurrent pneumonia.
Talking about esophageal dysphagia signs and symptoms
includes sensation of food sticking in the chest or throat,
change in dietary habits, recurrent pneumonia, heartburn,
belching, sour regurgitation, and water brash [21, 22].
In this review, we systematically described typical fea-
tures of swallowing disorders in rheumatic pathologies
mainly evaluating functional disorders and correlating path-
ological features and videoﬂuorographic ﬁndings.
VFSS ﬁndings provide information about disease severity
through the evaluation of swallowing deﬁcits and could have
also a role in the therapy management of the patient.
5. Scleroderma
SSc is a multisystemic chronic disease characterized by
abnormalities of small blood vessels (vasculitis) and extent
ﬁbrosis of both the skin and internal organs [7]. Due to
vasculitis and ﬁbrosis, a direct damage to gastrointestinal
organs such as vascular injury and consequent ischemia,
neurodegeneration, muscular atrophy, and ﬁbrosis could
be induced [7, 23].
In 1994, Sjogren proposed a progression of SSc character-
ized by gastrointestinal involvement, vascular damage,
neurogenic impairment, and myogenic dysfunction with
replacement of normal smooth muscle by collagen ﬁbrosis
and atrophy. For these patients, gastrointestinal involvement
represents the second most common site of damage caused
by the pathology, both in limited cutaneous SSC and in
diﬀuse cutaneous SSC, aﬀecting more than 80% of patients.
In particular, when the replacement of the smooth muscle
layers of the esophagus by ﬁbrous tissue takes over, muscle
contraction diminishes and the motility could be modiﬁed.
It has been reported that 87% of patients with progressive
systemic sclerosis complained from dysphagia [24].
Other mechanisms may aﬀect swallowing function, such,
for example, perioral skin and temporomandibular joint lim-
itation may lead to diﬃculty of the oral phase of deglutition
or mucous membrane atrophy may lead to impaired taste,
eating problems, and, consequently, weight loss [24].
Esophageal involvement may occur with symptoms of
heartburn and dysphagia [25].
However, symptoms may be poorly correlated with
abnormalities [26, 27].
Poor emptying of the esophagus, immunosuppressive
therapy, and acid suppression are also predisposing factors
to Candida infection [28, 29].
Consequences of the direct involvement of esophagus by
the pathology are stricture formation, Barrett’s metaplasia,
and carcinoma [30].
More rare complications are described in literature such
as esophageal left atrial ﬁstula in CREST syndrome (calcino-
sis, Raynaud’s phenomenon, esophageal dysmotility, sclero-
dactilia, and teleangiectasia), secondary to perforation of an
ulcer in Barrett’s esophagus [31].
5.1. VFSS Findings. VFSS in SSc is important because it
investigates both oropharyngeal and esophageal swallow
function evaluating both abnormalities of oropharyngeal
and esophageal swallowing and the impaired clearance of
the esophagus [32].
VFSS in SSc may identify epiglottal tilting with associ-
ated intraswallowing laryngeal penetration (Figure 1) and
pooling of contrast agent in the valleculae (Figure 2)
and/or pyriform sinuses [33]. As nonspeciﬁc sign that is
sometimes detected is the presence of hypertrophy of lin-
gual and/or palatine tonsils.
During the esophageal phase study, common ﬁndings are
weak or absent distal esophageal peristalsis and hypotensive
LES pressure, also deﬁned as scleroderma esophagus (even
when SSc is not present). Hence, esophageal dyskinesia,
esophageal dilatation, esophageal clearing deﬁcit, hiatus her-
nia, and gastroesophageal reﬂux may be found in SSc [33]. In
some cases, it is has been reported the presence of multiple
antiperistaltic waves of contraction, which produced a cork-
screw (Figure 3) esophagus [33].
As a consequence of esophageal dilatation sometimes
associated with hiatal hernia, reﬂux esophagitis may be
encountered: on VFSS, it will appear as a reticular mucosal
pattern, particularly located adjacent to a stricture [34, 35].
Dysmotility is also responsible of impaired acid clearance
with a prolongation of esophageal exposure time to gastric
acid leading to gastroesophageal reﬂux disease (GERD),
which could be considered the cause of alterations of epiglot-
tal tilting with laryngeal penetration of contrast agent [33].
Table 1: American Speech andHearingAssociation (ASHA)—adult
assessment template: videoﬂuoroscopic swallowing exam form.
Proposal for VFSS template
(1) Firstly, specify patient’s identiﬁcative information; past, recent,
surgical, and familiar medical history; past or recent
medications.
(2) Focus on the reason of the examination and patient’s subjective
symptoms.
(3) State the patient’s position during the procedure and specify
if cooperation by the patient is enough to achieve a diagnostic
exam.
(4) Indicate the types of barium meal used, bolus’ volumes, and
textures administered to the patient.
(5) Specify if swallowing abnormalities (aspiration, penetration,
swallow delay, and residue) are present or absent and if they
occur before, during, or after swallow.
(6) Highlight swallowing abnormalities of every swallowing phase
(oral, pharyngeal, and esophageal phase).
(7) Specify if backﬂow is observed during esophageal phase.
(8) Report provocative or therapeutic maneuvers.
(9) Specify and characterize the swallowing diagnosis of dysphagia
or, if swallowing process is not impaired, highlight the normal
limits of the diﬀerent phases.
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As extreme consequence of the disease, esophagus may
appear with a “rubber-hose”morphology due to extent atony
resulting in esophageal dilatation, with multiple waves of
superﬁcial and nonpropulsive contraction involving the
entire organ. In this case, the esophageal clearing is obtained
only through the upright position [33].
Concluding, severe esophageal impairment, linked to
reduction or absence of peristaltic waves, reduced pressure
of the lower esophageal sphincter, hiatus hernia, and delayed
gastric emptying and GERD correlate with a reduction of
clearing in association with changes of pressure in the
LES [36, 37]. These factors may lead to inﬂammation
and Barrett’s esophagus [38].
6. Eosinophilic Fasciitis
Eosinophilic fasciitis, also called Shulman syndrome, is a very
rare, localized ﬁbrosing disorder of the fascia. Approximately
300 cases [39] have been reported in the medical literature.
The etiology and pathophysiology are unclear [39]. It has
been also classiﬁed by some authors [39] as scleroderma-
like syndromes.
Eosinophilic fasciitis aﬀects both sexes. Some reports
[39, 40] suggest that women are aﬀected with greater fre-
quency than men. The disorder can occur at any age,
but most often occurs in individuals between 30–60 years.
It occurs with greater frequency in Caucasians.
The ﬁrst symptoms were noticed at an average of 8.8± 6.1
months before diagnosis [39].
In 1974, Shulman provided an early description of eosin-
ophilic fasciitis as a disorder characterized by peripheral
eosinophilia and fasciitis that could be diﬀerentiated from
scleroderma by the distinctive pattern of skin involvement
that spares the digits, involves fascia rather than dermis,
and is not accompanied by Raynaud phenomenon [40–43].
The internal organs (viscera) may be aﬀected in some
cases, although only mildly.
6.1. VFSS Findings. Considering that Eosinophilic fasciitis is a
scleroderma-like syndrome, VFSS ﬁndings are similar to the
ones described for SSc. In particular, it has been reported the
direct involvement of gastrointestinal system, especially of
the esophagus. Common features are related to the deposi-
tion of immunoglobulin complex that induces a dysmotility
disorder characterized by an impairment of waves of contrac-
tion. This feature may involve the entire esophagus especially
the second part and third part of the lower esophagus. An
increasing involvement may induce to progression of symp-
toms and imaging features due to hypokinesia of the whole
esophagus, which may appear atonic on VFSS, sometimes
with evidence of hiatal hernia.
The incontinence of LES produce a continuous exposure
to gastric acid ﬂuids that evolve in reﬂux esophagitis. In
advanced disease, a common ﬁnding is represented by extent
atony with typical GERD ﬁndings [43].
Figure 1: Videoﬂuorographic study performed in a 47-year-old male with diagnosis of scleroderma. The lateral view shows the presence of
intraswallowing laryngeal penetration with tracheal painting (arrow).
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7. Sjogren Syndrome
SS is an autoimmune disease that primarily aﬀects the exo-
crine glands (mainly the salivary and lacrimal glands) and
results in the severe dryness of mucosal surfaces, principally
in the mouth and eyes. Symptoms can include dry skin, a
chronic cough, vaginal dryness, numbness in the arms and
legs, and general symptoms as fatigue, muscle and joint
pains, and thyroid problems [44]. About 70% of patients
aﬀected by SS develops dysphagia [45, 46], and the causes
are related to a combination of lack of saliva, esophageal
dysmotility, esophageal web, achalasia (Figure 4), exocrine
gland involvement, low grade myositis, and parasympa-
thetic function damage [47–49]. Both prolonged pharyn-
geal transit time and absence of saliva predispose to
dental caries and Candida. Moreover, a delayed clearance of
the esophagus may lead a major exposure to acid [47, 48].
These features result in direct involvement of both pha-
ryngeal and esophageal phases of deglutition. Moreover,
esophageal symptoms sometimes do not correlate with
results from investigations.
The disease predominantly aﬀects middle-aged women,
but can also be observed in children,men, and the elderly [44].
Figure 2: A 57-year-old female patient with scleroderma. Anteroposterior view highlights the presence of pooling contrast agent in the
valleculae and pyriform sinuses due to altered motility.
Figure 3: A 45-year-old female with scleroderma. Exam performed
in the supine position, in the anteroposterior view. During
deglutition, it is possible to highlight the presence of multiple
tertiary antiperistaltic waves (arrows) in the whole esophagus; this
pattern is known as corkscrew esophagus.
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It is sometimes linked to other diseases such as rheuma-
toid arthritis and lupus. In Sjogren’s syndrome, glands that
make tears and saliva are aﬀected causing dry mouth and
dry eyes, also called as syndrome sicca [44].
7.1. VFSS Findings. In SS, pharyngeal transit time increases
and patient needs more time to start deglutition with a result-
ing hesitation and in some nonpropulsive movements of ton-
gue. It could be deﬁned as the diﬃculty initiating swallowing.
It has also been often described aperistalsis in the upper
10 cm; in other cases, it has been reported aperistalsis in the
whole esophagus especially during dry swallows (Figure 5).
The upper esophagus may be involved also by the
presence of triphasic tertiary contractions or nonperistaltic
contractions; however, these ﬁndings could be common
also in the whole organ. In only one study, it has not been
reported any abnormality of the upper or lower esophageal
sphincter [50].
A shorter peristaltic contraction time of the whole
esophagus in association with a faster peristaltic velocity
preferably in the distal part of the esophagus has also been
reported [51].
Achalasia may also be detected [51]. In this case, com-
mon ﬁndings are represented by reduction of esophageal
clearing time in association with aperistalsis; moreover, espe-
cially in advanced stage of pathology, it could be recognizable
an air-ﬂuid level, classiﬁed on the base of the location in dis-
tal, intermediate, or proximal; at least, esophagus-gastric
junction has been described very thin with the typical sign
of mouse tail [52].
8. Sarcoidosis
The incidence of sarcoidosis averages 1 : 10.000 in the
western world [53].
Figure 4: A 54-year-old woman with Sjogren syndrome. Videoﬂuorographic swallowing study demonstrates the bird-beak (arrow)
appearance of the lower esophagus, dilatation of the esophagus, and stasis of barium in the esophagus.
Figure 5: A 54-year-old woman with Sjogren syndrome.
Videoﬂuorographic swallowing study demonstrates atonic
esophagus with “rubber-hose” appearance and associated achalasia.
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Sarcoidosis is an inﬂammatory, granulomatous, multi-
system disorder of unclear etiology [1]. The lungs are pre-
dominantly involved, but it can entail involvement of any
other organ or organ systems such as the skin, lymphatics,
heart, musculoskeletal, neurological, and gastrointestinal
system [54–56].
It has the highest incidence in the United States and
Sweden [57]. In the United States, it is more common in
African Americans with an age adjusted annual incidence
rate of 35.5 in 100,000, whereas in Caucasians it is 10.9
in 100,000 [57]. The lifetime risk of developing sarcoidosis
is 2.4% in African Americans compared to 0.85% in
whites [58].
Sarcoidosis tends to aﬀect individuals aged 40 years or
younger [57].
While gastrointestinal involvement of sarcoidosis is seen
very infrequently, esophageal involvement of sarcoidosis is
extremely a rare occurrence in sarcoidosis. A review of the
literature revealed only 23 published cases of esophageal
involvement in sarcoidosis to date [59–62].
In the cases reported in literature, patients swallowing
diﬃculty was deﬁned by stenosis of the distal esophagus.
Even though, dysphagia is the most common symptom in
patients aﬀected by sarcoidosis with esophageal involvement
[63]. The esophageal involvement in sarcoidosis has been
classiﬁed in literature based upon two criteria: the level of
involvement and the layer of involvement [62].
Focusing on the site of involvement, symptoms and
diagnostic features depend on them. Superﬁcial involvement
of the mucosa may manifest macroscopically as mucosal
hyperemia, discrete plaque-like or nodular lesions, with,
sometimes, the appearance of Barrett’s esophagitis [64].
Myopathic involvement, however, is induced by direct inﬁl-
tration of skeletal muscle of the esophagus and pharynx
and could be classiﬁed into three distinct classes: nodular
lesions, acute myositis, and chronic myopathy [65].
Also, direct involvement of the enteric nervous plexus
can cause dysphagia, and, in this case, the clinical features
can mimic achalasia [66]. Development of strictures sec-
ondary to sarcoid involvement of the esophagus have also
been described [67]. It has also been reported a case of
worsening dysphagia resulting in both extrinsic compres-
sion by enlarge mediastinal nodes and neuromuscolar
dysfunction due to direct inﬁltration [63, 68]. However,
the lower esophagus was the most commonly involved
than the upper esophagus [69].
8.1. VFSS. As described before, diﬀerent mechanisms may
produce a direct or indirect involvement of the esophagus
in sarcoidosis. Videoﬂuorography can provide information
about pharyngeal phase of swallowing, status of the esopha-
geal sphincters, and peristalsis.
Concerning the ﬁrst part of the esophagus, it has been
reported a signiﬁcant narrowing at the level of pharyngoeso-
phageal junction with hypertony of UES, which could be
related to the direct inﬁltration of skeletal muscle of the
esophagus and pharynx [70].
An important feature is represented by the lack of peri-
stalsis in the esophageal body and an incomplete opening
of LES after swallowing, also resulting from inﬁltration of
both skeletal and smooth muscles.
It has also been reported a case of achalasia-like dysmoti-
lity in which VFSS ﬁndings were a mildly dilated esophageal
body with barium hold-up in the distal esophagus and a bird-
beak appearance of the esophagogastric junction. Pathologi-
cal mechanism is due to direct inﬁltration of nerves and mus-
culature of the esophageal wall [71].
In case of extrinsic compression by enlarged lympho-
nodes, videoﬂuorography shows a large mass deforming the
middle esophagus resulting in esophageal strictures [72].
Esophagus involvement is also been reported as a mide-
sophageal traction diverticulum secondary to inﬂamed medi-
astinal lymphonodes [73].
As already said, there have also been cases of Barrett’s
esophagitis [74]. Classic radiologic features of Barrett’s
esophagus consist of a high esophageal stricture or ulcer,
often associated with a hiatal hernia (Figure 6) or gastro-
esophageal reﬂux. The strictures may appear as ring-like con-
strictions or, less commonly, as smooth, tapered areas of
narrowing in the midesophagus. Barrett’s ulcers typically
appear as relatively deep ulcer craters within the columnar
mucosa at a considerable distance from the gastroesophageal
junction [75].
Occasionally, however, a reticular or villous pattern of the
mucosa may be observed as the only morphologic abnormal-
ity in Barrett’s esophagus [76].
9. Systemic Lupus Erythematosus
SLE is a chronic inﬂammatory disease characterized by dif-
ferent manifestations and following a relapsing and remitting
course. More than 90% of cases of SLE occur in women, fre-
quently starting at childbearing age [77].
Figure 6: A 56-year-old man with sarcoidosis. Videoﬂuorographic
swallowing study performed in the supine position. In the lateral
view, the presence of a little sliding hiatal hernia (arrow) is noticed
that could not be seen in orthostatism (not shown in this ﬁgure).
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Annual incidence of SLE from the 1970s to 2000s has
ranged from approximately 1 to 10 per 100,000 population,
while the prevalence of SLE has been estimated to range from
approximately 5.8 to 130 per 100,000 population [77].
Although the speciﬁc cause of SLE is unknown, multiple
genetic predispositions and gene-environment interactions
have been identiﬁed [78, 79].
Gastrointestinal manifestations are common in patients
with SLE. In 1985, William Osler emphasized that gastroin-
testinal manifestations in SLE may mimic any kind of
abdominal condition [80]. In particular, dysphagia occurs
in about 13% and heartburn in up to 50% of patients with
SLE. Esophagitis with ulceration has been observed in 3–5%
of patients [80].
The aetiopathological process causing esophageal dys-
motility in patients with SLE is uncertain, but both inﬂam-
mation of the esophageal muscles and vasculitic damage to
the Auerbach plexus could be responsible [81].
9.1. VFSS. VFSS in SLE may show hypoperistalsis and aperis-
talsis in about 72% of patients, while abnormality low or
absent contractions are found in the upper one-third of the
esophagus [81].
It has been reported also a prolonged pharyngeal transit
times, with no diﬀerence compared to patients with primary
Sjogren’s syndrome. In fact, both in SLE and in SS, the upper
one-third of esophagus is mainly aﬀected [82, 83].
The cause of the swallowing disorder is mainly related to
recurrent mouth ulcers in about 30% of patients and SS in
about 20%. It is also important to underline a potential cause
of dysphagia represented by Candida albicans, especially in
patients treated with immunosuppressive therapy [84].
Although involved, the LES is almost spared, if compared
with other autoimmune rheumatic diseases. However, dys-
phagic symptoms are related to GERD due to abnormal
peristalsis in both proximal and distal esophagus [29].
10. Idiopathic Inflammatory Myopathies
IIM is a group of systemic connective tissue disorders charac-
terized by inﬂammation of the muscles used for movement
(skeletal muscles), proximal symmetrical muscle weakness,
decreased muscle endurance, and chronic inﬂammation in
muscle tissue [84–86].
Idiopathic inﬂammatory myopathy usually appears in
adults between ages 40 and 60 or in children between ages
5 and 15, though it can occur at any age [85]. The incidence
of idiopathic inﬂammatory myopathy is approximately 2 to 8
cases per million people each year [85].
They can be subclassiﬁed into dermatomyositis, poly-
myositis, and inclusion body myositis (IBM) considering
diﬀerences in clinical and histopathological features [85, 87].
Polymyositis (PM) and dermatomyositis (DM) involve
weakness of the muscles closest to the center of the body
(proximal muscles), such as the muscles of the hips and
thighs, upper arms, and neck. In some cases, moreover phys-
ical diﬃculty, they may develop swallowing or breathing
diﬃculty due to muscle weakness.
Symptoms are similar, but polymyositis and dermatomy-
ositis are distinguished by a reddish or purplish rash on the
eyelids, elbows, knees, or knuckles.
The GI manifestations of the idiopathic inﬂammatory
myopathies include uncoordinated swallowing, uncoordi-
nated esophageal peristalsis, and hiatal hernia with reﬂux
and stricture formation [88].
From 8% to 30% of patients develops dysphagia, with
higher incidence in myositis-aﬀected patients [89, 90].
Esophageal motility is involved in every aspect consider-
ing the features of the disease: in particular, both skeletal and
smooth muscle function is impaired. Especially, UES func-
tion is impaired, more than in scleroderma [91].
Involvement of striatedmuscles of the pharynx and upper
esophagus occurs in 10–15% of cases andmay lead to dyspha-
gia and also regurgitation and aspiration pneumonia [92].
Dysphagia features depend on inﬂammation and dysmo-
tility of the upper and lower esophagus and cricopharyngeal
muscle dysfunction, which are responsible of a characteristic
sensation of food sticking in the back of the throat or cough-
ing with swallowing [93]. 70% of patients may present distal
esophageal abnormalities in the absence of proximal esopha-
geal involvement.
Distal dysmotility features are similar to scleroderma,
but not physiopathologically related. Dysmotility of the
lower esophagus is related to the duration of the primary
disease [88].
Thanks to these pathological mechanisms; it is possible
to recognize on one hand the formation of diverticula due
to degeneration of the skeletal muscle and weakness of
smooth ones, on the other hand, atony that may predis-
pose to GERD [94].
As in other rheumatic pathologies, immunosuppressive
therapy may predispose also to candidiasis and other esoph-
agitis such as herpetic, both herpes simplex and CMV [47].
At least, it is important to remember, as in other diseases,
that vasculitis may cause ulceration and even esophageal
perforation; however, it is more common in children.
Patients with IBM develop dysphagia in 40–80% of cases,
more than DM and PM [29].
At least, patients with dysphagia exclusively related to
cricopharyngeal dysfunction have a better prognosis if they
undergo myotomy [95].
10.1. VFSS. At a ﬁrst approach, before starting the exami-
nation, dysphonia with a nasal speech could be noted. It
could be also important to evaluate the involvement of
diaphragm and intercostal muscles, which may cause some
problems both in swallowing and in breathing during the
examination [92].
The triggering of the swallowing for the voluntary phase
is almost normal, but pharyngeal phase is often prolonged.
UES results hypotonic in majority of cases associated with a
tongue weakness and sphincter closing problem. Oropharyn-
geal swallowing problems include also the involvement of the
one-third proximal part of the esophagus, which is hypotonic
too [29].
When pharyngeal involvement is registered also in juve-
nile DM, it is associated with a poor prognosis, because it
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predisposes to a major risk of swallow dysfunction and
aspiration [96].
Most common abnormalities are residual pharyngeal
pooling, tongue base weakness, airway penetration, reduced
UES contraction, also as a prominent, tight cricopharyngeal
muscle with poor relaxation, and impaired laryngeal eleva-
tion. Aspiration during deglutition is also frequent [97].
Lower esophagus involvement is more common in distal
esophagus in IBM.
VFSS features are similar to SSc. Thus, there is a peristal-
tic decrease that may determine expansion of the lower
esophagus and a LES-impaired contraction. Moreover, dys-
motility leads to GERD. When prolonged, acid exposure
may cause reﬂux esophagitis characterized by reticular or
villous pattern of the mucosa [92].
In some cases it is possible to recognize diverticula that
appears, at VFSS, as round extroﬂession of mucosa with con-
trast pooling inside that may have diﬀerent dimension and
connection with the esophageal lumen [94].
11. Rheumathoid Arthritis
RA is an autoimmune disorder characterized by chronic
synovial inﬂammation that induce joint destruction and
bone erosions. Pathogenic mechanisms are not fully clear,
but it is known that both genetic and environmental factors
trigger an abnormal autoimmune response [98]. RA aﬀects
between 0.5 and 1% of adults in the developed world with
between 5 and 50 per 100,000 people newly developing the
condition each year [98].
Onset is uncommon under the age of 15, and from then
on, the incidence rises with age until the age of 80 [99].
Women are aﬀected three to ﬁve times as often as men [100].
The disease most commonly starts in women between 40
and 50 years of age [99]. A spontaneous remission may
occur; however, the natural course is almost invariably per-
sistent symptoms and a progressive deterioration of joint
structures leading to deformations and disability. Potentially,
any organ and tissue could be aﬀected. Gastrointestinal
involvement, especially dysphagia, is related to pharmaceutic
therapies, atlantoaxial subluxation, vasculitis that leads to
dysmotility, ﬁbrosis, stricture, and ulceration. Gravity
depends on disease severity or duration of RA [29, 49, 99].
11.1. VFSS. First part of examination may be altered by diﬃ-
culty of chewing and swallowing related to direct laryngeal
involvement by synovitis and nodules.
Temporomandibular joint involvement and sicca syn-
drome may also have a role in this phase of deglutition [101].
In the proximal esophagus, it has been reported a
decreased peristaltic pressure, related to striated muscle
dysfunction [102].
Characteristic features of RA are low-amplitude peristaltic
waves in the lower two-third of the esophagus and impaired
LES pressure, which may predispose to GERD [103].
In some cases, it could be recognized a stricture in the
lower esophagus due to the presence of esophageal varices,
related to Felty’s syndrome that induces a nodular hyperpla-
sia of the liver with portal hypertension [104].
In children with JRA, temporomandibular joint pain is
rarely reported and it results in compromised masticatory
function. Articular involvement is often associated with
dysphagia.
Other ﬁndings include decrease/impairment of distal
esophagus peristalsis and esophageal ulcers, maybe due to
esophageal reﬂux [105].
12. Vasculitis and Complications of
Antirheumatic Therapy
Vasculitis is a heterogeneous group of disease entities,
whose common feature is vascular wall damage through
inﬂammation caused by autoimmune processes. The sever-
ity of the disease depends on whether only skin and sub-
cutaneous tissue vessels are occupied or whether organ
alterations occur.
Vasculitis can also be induced by numerous drugs includ-
ing nonsteroidal anti-inﬂammatory drugs, antibiotics, anti-
hypertensive drugs, and so on.
Esophageal involvement in vasculitis has been largely
reported in literature [106].
In this group of pathologies, it should be remembered
Behcet disease, in which dysphagia is due to both oral and
esophageal ulcers, but only 3–26% of patients have GI
involvement [107].
In Henoch-Schonlein purpura, GI involvement includes
esophageal strictures [47] and carcinoma [108].
Many drugs used to treat musculoskeletal conditions can
aﬀect swallowing in various ways.
In fact, anti-inﬂammatory drugs, corticosteroids, and
bisphosphonates can cause esophagitis and esophageal
ulceration. Moreover, gold compounds (intramuscular and
oral), penicillamine, sulfasalazine, methotrexate, and other
cytotoxic drugs can cause oral ulcers and other lesions to
oral mucosa. Similarly, alendronate sodium has a toxic
eﬀect and a physical irritation of the mucosa caused by
the pill [109].
“Pill esophagitis” in fact is characterized by retrosternal
chest pain and possibly dysphagia, odynophagia, and symp-
toms that could be related also to GERD [30].
Candidiasis of the upper GI tract is also a frequent conse-
quence of steroid therapy and other immunosuppressive
agents. Gold-induced enterocolitis has been found histopath-
ologically to involve the esophagus as well as the stomach and
small bowel [110].
12.1. VFSS. Findings could be highly variable in relation to
the underlying mechanisms. In fact, it could be possible to
recognize a reduced UES contraction or an impaired peristal-
sis of two-third esophagus, from hypotony up to atony.
The presence of changes of pressure in the LES with con-
sequent incontinence produces a continuous exposure to
gastric acid ﬂuids, evolving in reﬂux esophagitis up to typical
GERD ﬁndings has been described [44].
Esophagitis may evolve Barrett’s esophagus [74] with its
classic radiologic features such as esophageal stricture or
ulcer, sometimes associated with hiatal hernia or gastro-
esophageal reﬂux [75].
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13. Conclusion
Despite the heterogeneity of the wide range of rheumatic
diseases, swallowing disorders are frequently encountered
in all of them.
Due to the presence of diﬀerent mechanisms that may
determine swallowing disorders, potentially each stage of
deglutition can be altered.
The most important causes that determine a direct dam-
age of organs involved in deglutition are ﬁbrotic inﬁltration,
muscle degeneration, both smooth and skeletal, vascular
damage, node enlargement, which may attract part of esoph-
agus, and joint degeneration. The role of VFSS during years,
as both morphological and functional study, is already
deﬁned not only in the detection but also in the evaluation
of progression of the pathology. For these reasons, it is
important to consider VFSS as the gold standard in the com-
plete functional assessment of every phase of swallowing in
rheumatological diseases.
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